Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on April 7, 2008

Hypertension. 2008
Published online before print April 7, 2008, doi: 10.1161/HYPERTENSIONAHA.107.104463
A more recent version of this article appeared on May 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
51/5/1393    most recent
HYPERTENSIONAHA.107.104463v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ward, N. C.
Right arrow Articles by Croft, K. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ward, N. C.
Right arrow Articles by Croft, K. D.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Other hypertension
Right arrow Clinical Studies
Right arrow Other Vascular biology

Submitted on November 4, 2007
Revised on November 27, 2007

A Single Nucleotide Polymorphism in the CYP4F2 but not CYP4A11 Gene Is Associated With Increased 20-HETE Excretion and Blood Pressure

Natalie C. Ward*; I-Jung Tsai; Anne Barden; Frank M. van Bockxmeer; Ian B. Puddey; Jonathan M. Hodgson; and Kevin D. Croft

From the Schools of Medicine and Pharmacology (N.C.W., I-J.T., A.B., I.B.P., J.M.H., K.D.C.), and Surgery and Pathology (F.M.v.B.), University of Western Australia, Perth, Australia.

* To whom correspondence should be addressed. E-mail: nward{at}meddent.uwa.edu.au.

Abstract—Arachidonic acid is a major fatty acid that can be metabolized by the cytochrome P450 enzyme to a number of bioactive eicosanoids. A major metabolite of this oxidation is 20-hydroxyeicosatetraenoic acid, which acts as a potent vasoconstrictor. However, in the kidney, its vasoconstrictor actions can be offset by its natriuretic properties. A guanine-to-adenine polymorphism in the CYP4F2 gene was associated with a reduction in 20-hydroxyeicosatetraenoic acid production in vitro. A thymidine-to-cytosine polymorphism in the CYP4A11 gene reduced catalytic activity by >50% in vitro and was associated with hypertension. The aim was to determine whether these 2 mutations are associated with urinary 20-hydroxyeicosatetraenoic acid excretion and blood pressure in humans. For the CYP4F2, 51% were homozygous for the G allele, 40% were carriers, and 9% were homozygous for the A allele. For CYP4A11, 72% were homozygous for the T allele, 25% were carriers, and 3% were homozygous for the C allele. The CYP4F2 GA/AA genotype was significantly associated with an increase in both 20-hydroxyeicosatetraenoic acid excretion and systolic blood pressure. The CYP4A11 CC/TC genotype was significantly associated with a reduction in 20-hydroxyeicosatetraenoic acid excretion but was not associated with blood pressure. We have demonstrated for the first time in humans that polymorphisms of the CYP4F2 and CYP4A11 genes have opposite effects on 20-hydroxyeicosatetraenoic acid excretion. The positive association between the CYP4F2 GA/AA genotype and both systolic blood pressure and 20-hydroxyeicosatetraenoic acid excretion strengthens a role for 20-hydroxyeicosatetraenoic acid in the modulation of blood pressure.


Key words: cytochrome P450 • CYP4F2 V433M • CYP4A11 F434S • 20-HETE • blood pressure




This article has been cited by other articles:


Home page
HypertensionHome page
J. H.Y. Wu, J. M. Hodgson, M. W. Clarke, A. P. Indrawan, A. E. Barden, I. B. Puddey, and K. D. Croft
Inhibition of 20-Hydroxyeicosatetraenoic Acid Synthesis Using Specific Plant Lignans: In Vitro and Human Studies
Hypertension, November 1, 2009; 54(5): 1151 - 1158.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
K. Inoue, K. Sodhi, N. Puri, K. H. Gotlinger, J. Cao, R. Rezzani, J. R. Falck, N. G. Abraham, and M. Laniado-Schwartzman
Endothelial-specific CYP4A2 overexpression leads to renal injury and hypertension via increased production of 20-HETE
Am J Physiol Renal Physiol, October 1, 2009; 297(4): F875 - F884.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. Perez-Andreu, V. Roldan, A. I. Anton, N. Garcia-Barbera, J. Corral, V. Vicente, and R. Gonzalez-Conejero
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy
Blood, May 14, 2009; 113(20): 4977 - 4979.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. W. Nebert and C. L. Karp
Endogenous Functions of the Aryl Hydrocarbon Receptor (AHR): Intersection of Cytochrome P450 1 (CYP1)-metabolized Eicosanoids and AHR Biology
J. Biol. Chem., December 26, 2008; 283(52): 36061 - 36065.
[Full Text] [PDF]


Home page
HypertensionHome page
C. Fava, M. Montagnana, P. Almgren, L. Rosberg, G. Lippi, B. Hedblad, G. Engstrom, G. Berglund, P. Minuz, and O. Melander
The V433M Variant of the CYP4F2 Is Associated With Ischemic Stroke in Male Swedes Beyond Its Effect on Blood Pressure
Hypertension, August 1, 2008; 52(2): 373 - 380.
[Abstract] [Full Text] [PDF]